Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Pfizer rare heart disease drug reduces risk of death by 30 percent in study

      Pfizer rare heart disease drug reduces risk of death by 30 percent in study

      Ruby Khatun Khatun29 Aug 2018 9:30 AM IST
      NEW YORK: Pfizer Inc said that its drug tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent,...
      Health Ministry deliberating report on faulty hip Implant Case: Nadda

      Health Ministry deliberating report on faulty hip Implant Case: Nadda

      Ruby Khatun Khatun28 Aug 2018 12:18 PM IST
      Recalled in Australia, but approved in India in the same monthNew Delhi: Union Health Minister JP Nadda said his ministry is holding deliberations on...
      Lupin launches contraceptive drug in US

      Lupin launches contraceptive drug in US

      Ruby Khatun Khatun28 Aug 2018 11:00 AM IST
      New Delhi: Drug maker Lupin launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets, used to prevent...
      Abbott India lines up 100 product launches over the next 5 years

      Abbott India lines up 100 product launches over the next 5 years

      Ruby Khatun Khatun28 Aug 2018 10:30 AM IST
      New Delhi: Drug major Abbott India Ltd aims to launch around 100 products over the next five years as it looks to strengthen existing therapy areas as...
      Novartiss Kymriah wins EU approval for blood cancer treatment

      Novartis's Kymriah wins EU approval for blood cancer treatment

      Ruby Khatun Khatun28 Aug 2018 10:00 AM IST
      ZURICH: Swiss drugmaker Novartis received European Commission approval for Kymriah, its CAR-T cell therapy, to treat children with a form of leukemia...
      Bayer, Johnson and Johnson

      Bayer, Johnson and Johnson's heart drug Xarelto fails trial to widen use

      Ruby Khatun Khatun28 Aug 2018 9:45 AM IST
      FRANKFURT: Bayer and Johnson and Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential...
      FDA declines to approve Akcea-Ionis genetic disease drug

      FDA declines to approve Akcea-Ionis genetic disease drug

      Ruby Khatun Khatun28 Aug 2018 9:30 AM IST
      The U.S. Food and Drug Administration (FDA) declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a...
      Faulty Hip Implant Case Aftermath : Soon a Registry to track use of high-risk medical devices soon

      Faulty Hip Implant Case Aftermath : Soon a Registry to track use of high-risk medical devices soon

      Ruby Khatun Khatun27 Aug 2018 5:50 PM IST
      New Delhi: Soon a registry is going to take care of the use of medical devices which posses a high risk to the patients.TOI reports that the health...
      Racket: Rajasthan Government Procures Medicines, Private Chemists Sell them In Maharashtra

      Racket: Rajasthan Government Procures Medicines, Private Chemists Sell them In Maharashtra

      Ruby Khatun Khatun27 Aug 2018 1:16 PM IST
      Thane: Several chemists and distributors across the country have been booked by Maharashtra police for allegedly selling medicines procured by the...
      Fortis, RHT extend last date for completing acquisition

      Fortis, RHT extend last date for completing acquisition

      Ruby Khatun Khatun27 Aug 2018 11:53 AM IST
      New Delhi: Fortis Healthcare Ltd and RHT Health Trust have agreed to extend the last date for the acquisition of an entire portfolio of assets of the...
      Lupin enters prescription dermatology segment in Brazil

      Lupin enters prescription dermatology segment in Brazil

      Ruby Khatun Khatun27 Aug 2018 10:15 AM IST
      New Delhi: Drug maker Lupin said it has entered the prescription dermatology segment in Brazil with the launch of two products Fillerina and Recrexina...
      FDA approves Shire drug for rare swelling disorder

      FDA approves Shire drug for rare swelling disorder

      Ruby Khatun Khatun27 Aug 2018 9:45 AM IST
      The U.S. Food and Drug Administration (FDA) approved a first of its kind drug from Shire Plc to treat patients aged 12 and older suffering from a rare...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok